Samsung Biologics has announced the launch of its proprietary cell line technology, S-CHOice.
 
According to the company, S-CHOice builds on glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line technology and shows improved titers up to two-fold from industry average, reaching above 7 g/L for standard monoclonal antibodies. The cell line also shows enhanced cell viability with over 90% at day-21 in a fed-batch study, demonstrating effectiveness in producing high quality cell lines.
 
Moreover, S-CHOice has a speedy cell division of 18-20 hours and together with Berkeley Lights Beacon technology, Samsung Biologics says it can offer a reduced development timeline by a month from the industry average of four to five months.
 
The company will also provide payment terms for clients choosing to use this cell line technology for their future development.  
 
Leveraging these combination of advantages, Samsung Biologics recently signed a development contract with a client under which S-CHOice will be used to advance its cell line development.
 
“We are extremely proud to announce the official launch of our own proprietary cell line, S-CHOice,” said Dr. Tae Han Kim, CEO of Samsung Biologics. “With this advanced, high performance technology, we can now offer our CDO clients with even more promising options in bringing their molecule faster and better to the market and ensure world-class client satisfaction during this continuously evolving global climate.”